 Tricida Inc NASDAQ: TCDA has received an Appeal Denied Letter ADL from the Office of New Drugs OND of the FDA in response to the companys Formal Dispute Resolution Request FDRR submitted in December. The FDDR requested that the magnitude of serum bicarbonate change seen in the TRCA-301 and TRCA-301E trials is reasonably likely to predict clinical benefit in treating metabolic acidosis associated with chronic kidney disease CKD. 